Open AccessP1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Author(s) -
RussellSmith A.,
Shah R.,
Silverstein A.,
Petrilla A.,
Leinwand B.,
Norris D.,
Schroeder A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000849800.15938.16
Subject(s) - blinatumomab , medicine , health care , salvage therapy , pharmacy , oncology , pediatrics , chemotherapy , family medicine , lymphoblastic leukemia , leukemia , economics , economic growth